Pharmaceutical company, Merck & Co., has recently made a 3rd attempt to make the cholesterol lowering drug, Mevacor, available to consumers over-the-counter.
Since 2000, the Food and Drug Administration (FDA) has rejected the attempts due to possibly too many of the wrong people using Mevacor and risking unnecessary side effects.
Merck & Co. defended their case by arguing that only 6 million of 20 million Americans who have moderately high cholesterol are being treated. Merck believes that consumers have enough knowledge about heart-clogging cholesterol to use the drug properly.
The FDA’s scientific advisors will make a recommendation on Thursday, December 14th. However, they don’t know how long it will be to officially come to a decision on the issue.
For more information on this subject, please refer to the section on Mevacor / Lovastatin: Overview.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.